Sponsored By
A&M Stabtest
Event Sponsor
A&M STABTEST a full service CRO for Biopharmaceuticals, ASO and mRNA A&M STABTEST is a full-service CRO dedicated to analytical development, stability and release testing of Biopharmaceuticals and antisense oligonucleotides (ASO) and mRNA since 1995. Located in the heart of Europe, our team of 340 highly skilled staff take care of all aspects from sample logistics and storage, functional testing of devices, pharmaceutical testing incl. cell-based potency testing, to LC-MS based product characterization. As a company owned and managed by scientists, we take pride in being recognized as an innovative science-driven organization, capable of developing analytical solutions for our clints enabling them to take their innovative drugs to the market. With all Biopharma, ASO and mRNA services performed at one site, we truly offer a “Under-One-Roof-Shop” for highest quality pharmaceutical testing. For more information, please contact Dr. Steven Am Watt at steven.watt@am-labor.de
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Feinstein Institutes Links Blood Biomarkers to Psychosis in Alzheimer's Patients
The global aging population means that rates of Alzheimer's disease are expected to reach 14 million patients by 2060, many of whom will experience psychosis.
Meet Our Expert Speakers
Oligo Chemistry & Therapeutics Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Confirmed speakers include:
Anna Rydzik
Principal Scientist,
xx
Brooke Koshel
Director, Process Development,
Wave Life Sciences
Isaac Marks
Senior Scientist, Chemistry,
Avidity
Sasha Ebrahimi
Principal Investigator and Associate Fellow,
GSK
Ulrike Rieder
Scientific Lead,
Novartis